Semaglutide and Kidney Stones: What the Research Currently Shows

What clinical data actually shows about semaglutide and kidney stones

The direct question, can Wegovy cause kidney stones?, has been studied in real-world datasets as GLP-1 use has scaled up. A 2023 study drawing on US insurance claims data (involving hundreds of thousands of patients on GLP-1 receptor agonists including semaglutide) found that kidney stone incidence was not higher in GLP-1 users than in comparator groups on other antidiabetic or weight-management treatments. A separate analysis published in JAMA Internal Medicine found GLP-1 agonist use was associated with a lower rate of kidney stone episodes compared with other agents. These are observational findings, not randomised trials, so they can't prove cause and effect. What they do tell us is that semaglutide does not carry the kind of signal that would flag kidney stones as a recognised side effect, a point consistent with the NHS medicines information for semaglutide, which does not list kidney stones in its side effect profile. Our page looking at kidney stones and Wegovy brings together what the published evidence says for anyone who wants a deeper read on the subject.

The plausible biology behind a protective signal: obesity itself raises stone risk, particularly for uric acid stones. Weight loss reduces serum uric acid, lowers urinary calcium excretion in some individuals, and may reduce insulin resistance, all changes that shift the urinary chemistry away from stone formation. That said, none of this is settled enough to reassure someone who already forms stones without their prescriber's input.

The real risk to watch for: dehydration during GLP-1 treatment

There is one way that semaglutide could indirectly nudge stone risk upward, and it is worth taking seriously. The most common side effects of Wegovy are gastrointestinal (nausea, vomiting, and reduced appetite) and they are most pronounced in the early weeks of treatment or after a dose increase. If nausea puts you off drinking enough water, urine becomes more concentrated, which is exactly the environment in which stones form. This is not a theoretical concern: urologists have flagged dehydration as an underappreciated risk in GLP-1 patients, and the NHS patient information for semaglutide specifically advises contacting a doctor if vomiting or diarrhoea leads to dehydration. For a broader look at how the drug interacts with renal physiology, our page on semaglutide and the kidney explains the mechanisms in plain language. For anyone who has had a stone before, adequate fluid intake is not optional. The practical rule most prescribers give (aim for pale yellow urine throughout the day) is harder to follow when you feel queasy, but it matters. If you can't keep fluids down for more than a day or two, contact your prescriber or GP rather than waiting it out.

Our guide to kidney pain and Wegovy covers how to tell GLP-1-related flank discomfort from something that needs same-day assessment.

Who should have a more careful conversation before starting Wegovy

Does semaglutide cause kidney stones in people already prone to them? The honest answer is that the trials were not designed to answer this for high-risk stone formers specifically. If you have had recurrent calcium oxalate stones, uric acid stones, or a structural kidney abnormality, that context changes the risk-benefit calculation in ways that a prescriber needs to weigh with you directly. For a closer look at the evidence on how the drug acts on renal tissue, our page covering the effect of semaglutide on the kidneys sets out what current research shows. The same applies if you have reduced kidney function: semaglutide is used with caution in severe renal impairment, and NICE's appraisal of semaglutide (Wegovy) under TA875 does not exclude people with kidney disease as a group, but appropriate monitoring matters. A prescriber reviewing your summary care record and current medications is better placed than any general article to make that call. Our page on semaglutide and kidney disease goes further into what the clinical guidance says for people with impaired renal function.

Separately, anyone considering Wegovy who is pregnant, trying to conceive, or breastfeeding should know that semaglutide is not recommended in any of these situations. A different plan is needed, and your GP or specialist can advise. For context on Wegovy's broader safety profile during pregnancy, see our Wegovy and pregnancy page.

How to raise this at your consultation

If kidney stones are part of your medical history, the clearest thing you can do is mention them at the start of your consultation, not as an afterthought. Our prescribers at nume review each consultation personally before any prescription is issued; a named clinician reads your answers, not software. That means details like past stone episodes, current kidney function, or medications that interact with urinary chemistry (certain diuretics, for instance) actually get considered. If you are already on Wegovy through another provider and develop flank pain or notice blood in your urine, don't wait until your next scheduled review. Get it assessed the same day, your GP, an urgent treatment centre, or 111. You can also report unexpected symptoms to the MHRA via the Yellow Card scheme, which is how post-market safety signals for medicines like semaglutide are tracked.

If you would like to explore whether Wegovy is appropriate for you, speak to our prescribers through a free consultation, order by 12pm Monday to Friday and, if clinically approved, treatment is dispatched the same day.